IN2012DN03799A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03799A IN2012DN03799A IN3799DEN2012A IN2012DN03799A IN 2012DN03799 A IN2012DN03799 A IN 2012DN03799A IN 3799DEN2012 A IN3799DEN2012 A IN 3799DEN2012A IN 2012DN03799 A IN2012DN03799 A IN 2012DN03799A
- Authority
- IN
- India
- Prior art keywords
- diseases
- disorders
- sirtuin
- modulating compounds
- modulating
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25626909P | 2009-10-29 | 2009-10-29 | |
| PCT/US2010/054880 WO2011059839A1 (fr) | 2009-10-29 | 2010-10-29 | Pyridines bicycliques et analogues en tant que modulateurs de la sirtuine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03799A true IN2012DN03799A (fr) | 2015-08-28 |
Family
ID=43991957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3799DEN2012 IN2012DN03799A (fr) | 2009-10-29 | 2010-10-29 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9556201B2 (fr) |
| EP (1) | EP2493888B1 (fr) |
| JP (1) | JP2013509442A (fr) |
| KR (1) | KR20120092141A (fr) |
| CN (1) | CN102725291B (fr) |
| AU (1) | AU2010319842A1 (fr) |
| BR (1) | BR112012010010A2 (fr) |
| CA (1) | CA2779303A1 (fr) |
| ES (1) | ES2574927T3 (fr) |
| IL (1) | IL219372A0 (fr) |
| IN (1) | IN2012DN03799A (fr) |
| MX (1) | MX2012004995A (fr) |
| RU (1) | RU2550821C2 (fr) |
| WO (1) | WO2011059839A1 (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0820669A2 (pt) | 2007-12-10 | 2020-08-04 | Novartis Ag | compostos orgânicos |
| CA2738794C (fr) | 2008-09-29 | 2016-01-05 | Sirtris Pharmaceuticals, Inc. | Analogues de chromenone en tant que modulateurs de sirtuine |
| EA029892B1 (ru) | 2012-04-25 | 2018-05-31 | Такеда Фармасьютикал Компани Лимитед | Азотсодержащее гетероциклическое соединение |
| EP2847198B1 (fr) | 2012-05-08 | 2016-12-14 | Lycera Corporation | Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de ror-gamma et dans le traitement d'une maladie |
| RU2014149136A (ru) | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| JP6205356B2 (ja) | 2012-07-13 | 2017-09-27 | 武田薬品工業株式会社 | 複素環化合物 |
| EP2890698B1 (fr) * | 2012-08-30 | 2017-03-01 | F. Hoffmann-La Roche AG | Composés dioxino- et oxazine-[2,3-d]pyrimidine, inhibiteurs de pi3k, et leurs procédés d'utilisation |
| CN102977117A (zh) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 一种6-溴-2,2-二甲基-2h-吡啶并[3,2-b][1,4]恶嗪-3(4h)-酮的合成方法 |
| GEP201606554B (en) * | 2012-12-26 | 2016-10-10 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
| EP2975031A4 (fr) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
| JP6376707B2 (ja) | 2013-05-13 | 2018-08-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節剤としての置換架橋尿素類似体 |
| WO2016081692A2 (fr) * | 2014-11-19 | 2016-05-26 | Glaxosmithkline Llc | Analogues d'urée pontés substitués utilisés comme modulateurs de la sirtuine |
| JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
| EP3018126A4 (fr) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | Composé hétérocyclique |
| DK3929196T3 (da) | 2013-09-24 | 2023-09-25 | Fujifilm Corp | Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf |
| US10172915B2 (en) | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
| CN105683188B (zh) | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| WO2015095795A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Tétrahydronaphtyridine, benzoxazine, aza-benzoxazine et composés bicycliques apparentés pour l'inhibition de l'activité de rorgamma et le traitement de maladie |
| WO2015095788A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie |
| WO2015095792A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Acides propioniques de carbamate benzoxazine et dérivés acides pour la modulation de l'activité de rorgamma et le traitement de maladie |
| JP6510539B2 (ja) | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
| AU2015222917A1 (en) | 2014-02-27 | 2016-09-15 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| JP2017114764A (ja) * | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
| EP3140291A4 (fr) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Sulfonamide de tétrahydroquinoline et composés apparentés destinés à servir d'agonistes de rory et pour le traitement de maladies |
| WO2015171558A2 (fr) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| ES2756748T3 (es) | 2014-10-03 | 2020-04-27 | Novartis Ag | Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4 |
| CN107207520A (zh) * | 2014-11-19 | 2017-09-26 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 作为沉默调节蛋白调节剂的取代的桥环脲类似物 |
| CA2975997A1 (fr) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Composes pyrazole substitues utilises en tant qu'inhibiteurs de rorgammat et utilisations desdits composes |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| WO2016179343A1 (fr) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Sulfonamides de dihydro-2h-benzo[b][1,4]oxazine et composés apparentés destinés à être utilisés comme agonistes de rorγ et pour le traitement de maladies |
| CN107980042B (zh) | 2015-06-11 | 2021-10-08 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
| JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
| EP3368516B1 (fr) | 2015-10-27 | 2020-07-15 | Merck Sharp & Dohme Corp. | Composés pyrazoles bicycliques substitués en tant qu'inhibiteurs de rorgammat et leurs utilisations |
| US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN106243045A (zh) * | 2016-07-27 | 2016-12-21 | 常州大学 | 一种2,5‑二甲氧基‑4‑氨基嘧啶的制备方法 |
| JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| PT3538525T (pt) | 2016-11-08 | 2022-08-16 | Bristol Myers Squibb Co | Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina |
| LT3552017T (lt) | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| US9969768B1 (en) | 2017-11-16 | 2018-05-15 | King Saud University | Oleanolic acid methyl ester derivatives |
| GB201817047D0 (en) | 2018-10-19 | 2018-12-05 | Heptares Therapeutics Ltd | H4 antagonist compounds |
| GB202019667D0 (en) * | 2020-12-14 | 2021-01-27 | Heptares Therapeutics Ltd | H4 antagonist comnpounds |
| CN116354937B (zh) * | 2021-12-27 | 2025-07-11 | 江苏恩华药业股份有限公司 | 吡啶(嘧啶)胺类衍生物及其应用 |
| EP4463229A1 (fr) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Formes cristallines de ((s)-5-benzyl-n-(5-méthyl-4-oxo-2, 3,4,5- tétrahydropyrido [3,2-b] [l,4]oxazépin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| CN117362286B (zh) * | 2023-12-08 | 2024-03-12 | 清华大学 | 具有sirt6激动活性的化合物及其用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
| ATE437876T1 (de) * | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
| EP1817025A2 (fr) * | 2004-11-23 | 2007-08-15 | PTC Therapeutics, Inc. | Tetrahydrocarbazoles en tant qu'agents actifs permettant d'inhiber la production de vegf par regulation de la traduction |
| CA2599992A1 (fr) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Modulateurs de la sirtuine a base d'acridine et de quineoline |
| WO2006094246A2 (fr) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Modulateurs de sirtuine a base de n-arylmethyl benzamide |
| ATE544071T1 (de) | 2005-03-03 | 2012-02-15 | Sirtris Pharmaceuticals Inc | Fluoreszenzpolarisationstests für die acetyltransferase-deacetylase-aktivität |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| WO2006094248A1 (fr) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Modulateurs de sirtuine cycliques a substitution aryle |
| WO2006094233A1 (fr) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Modulateurs de sirtuine isothiourée n,n’-dicyclique |
| US20090163476A1 (en) | 2005-03-03 | 2009-06-25 | Sirtris Pharmaceuticals, Inc. | N-Phenyl Benzamide Derivatives as Sirtuin Modulators |
| WO2006094210A2 (fr) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Modulateurs de sirtuine de tetrahydroquinoxalinone |
| US20070014833A1 (en) | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| EP2805719A1 (fr) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside et analogues |
| CA2609549A1 (fr) | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Traitement de troubles oculaires par modulateurs de sirtuine |
| DE102005026762A1 (de) * | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
| AU2006269459B2 (en) | 2005-07-07 | 2013-02-07 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7345178B2 (en) | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US20070248590A1 (en) | 2005-12-02 | 2007-10-25 | Sirtris Pharmaceuticals, Inc. | Modulators of CDC2-like kinases (CLKS) and methods of use thereof |
| EP1955077B1 (fr) | 2005-12-02 | 2012-06-13 | Sirtris Pharmaceuticals, Inc. | Dosages biologiques par spectrometrie de masse destines a determiner une activite d'acetyltransferase/desacetylase |
| DE102006014685A1 (de) * | 2006-03-28 | 2007-10-04 | Sanofi-Aventis | Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen |
| WO2008027379A2 (fr) | 2006-08-29 | 2008-03-06 | Sirtris Pharmaceuticals, Inc. | Indicateurs d'activité sirtuine et procédés d'utilisation de ceux-ci |
| WO2008060400A2 (fr) | 2006-11-15 | 2008-05-22 | Sirtris Pharmaceuticals, Inc. | Polymorphismes de sirtuine, et leurs procédés d'utilisation |
| WO2008073451A2 (fr) | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Composés modulateurs de la sirtuine |
| US20080249130A1 (en) | 2007-02-09 | 2008-10-09 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
| WO2008100376A2 (fr) | 2007-02-15 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Variants de troncature de sirt1 et procédés d'utilisation de ceux-ci |
| CA2680823A1 (fr) | 2007-03-19 | 2008-09-25 | Sirtris Pharmaceuticals, Inc. | Biomarqueurs de l'activite sirtuine et procedes d'utilisation de ceux-ci |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| TW200918542A (en) | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| EP2215066A1 (fr) | 2007-11-01 | 2010-08-11 | Sirtris Pharmaceuticals, Inc. | Dérivés d'amide comme modulateurs de sirtuines |
| JP2011503066A (ja) | 2007-11-08 | 2011-01-27 | サートリス ファーマシューティカルズ， インコーポレイテッド | 可溶化チアゾロピリジン誘導体 |
| WO2009085226A2 (fr) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation |
| WO2009089011A2 (fr) | 2008-01-08 | 2009-07-16 | Sirtris Pharmaceuticals, Inc. | Formulations de resvératrol |
| AU2009243006B2 (en) | 2008-05-01 | 2013-03-21 | Sirtris Pharmaceuticals, Inc. | Quinolines and related analogs as sirtuin modulators |
| EP2285977A1 (fr) | 2008-05-15 | 2011-02-23 | Sirtris Pharmaceuticals, Inc. | Variants polymorphiques de sirtl et procédés d'utilisation de ceux-ci |
| CN102112475A (zh) | 2008-05-29 | 2011-06-29 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物 |
| BRPI0914006A2 (pt) | 2008-07-03 | 2015-10-27 | Sirtris Pharmaceuticals Inc | benzimidazóis e análogos relacionados como moduladores de sirtuína |
| WO2010019606A1 (fr) | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles et analogues apparentés en tant que modulateurs de la sirtuine |
| EP2341052A4 (fr) * | 2008-09-05 | 2011-10-12 | Shionogi & Co | Derive de morpholine à cycles condensés ayant une activite inhibitrice de pi3k |
| CA2738794C (fr) | 2008-09-29 | 2016-01-05 | Sirtris Pharmaceuticals, Inc. | Analogues de chromenone en tant que modulateurs de sirtuine |
| EP2350051A4 (fr) | 2008-10-29 | 2012-05-30 | Sirtris Pharmaceuticals Inc | Pyridine, pyridine bicyclique et analogues associés en tant que modulateurs de sirtuine |
| JP5590040B2 (ja) * | 2008-11-12 | 2014-09-17 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのピラジノピラジンおよび誘導体 |
| CA2746221A1 (fr) | 2008-12-08 | 2010-07-08 | Sirtris Pharmaceuticals, Inc. | Isoindolinone et analogues apparentes comme modulateurs de sirtuine |
| AU2009333251A1 (en) | 2008-12-16 | 2011-07-07 | Sirtris Pharmaceuticals, Inc. | Phthalazinone and related analogs as sirtuin modulators |
| CN102388054B (zh) | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| WO2010088574A1 (fr) | 2009-01-30 | 2010-08-05 | Sirtris Pharmaceuticals, Inc. | Azabenzimidazoles et analogues apparentés en tant que modulateurs de la sirtuine |
| CA2754058A1 (fr) | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | Quinoleines substituees en 8 et analogues associes utilises comme modulateurs de sirtuine |
| ES2626246T3 (es) * | 2009-09-09 | 2017-07-24 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de 8-oxodihidropurina |
| WO2011116176A1 (fr) | 2010-03-17 | 2011-09-22 | Sirtris Pharmaceuticals Inc. | Pyridines imidazo (4, 5-b) 3-substituées et analogues utilisés comme modulateurs de sirtuines |
-
2010
- 2010-10-29 WO PCT/US2010/054880 patent/WO2011059839A1/fr not_active Ceased
- 2010-10-29 EP EP10830519.4A patent/EP2493888B1/fr active Active
- 2010-10-29 ES ES10830519.4T patent/ES2574927T3/es active Active
- 2010-10-29 US US13/504,134 patent/US9556201B2/en not_active Expired - Fee Related
- 2010-10-29 BR BR112012010010A patent/BR112012010010A2/pt not_active IP Right Cessation
- 2010-10-29 CA CA2779303A patent/CA2779303A1/fr not_active Abandoned
- 2010-10-29 IN IN3799DEN2012 patent/IN2012DN03799A/en unknown
- 2010-10-29 CN CN201080060180.2A patent/CN102725291B/zh not_active Expired - Fee Related
- 2010-10-29 AU AU2010319842A patent/AU2010319842A1/en not_active Abandoned
- 2010-10-29 JP JP2012537157A patent/JP2013509442A/ja not_active Ceased
- 2010-10-29 KR KR1020127013635A patent/KR20120092141A/ko not_active Ceased
- 2010-10-29 MX MX2012004995A patent/MX2012004995A/es not_active Application Discontinuation
- 2010-10-29 RU RU2012122065/04A patent/RU2550821C2/ru not_active IP Right Cessation
-
2012
- 2012-04-23 IL IL219372A patent/IL219372A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9556201B2 (en) | 2017-01-31 |
| RU2012122065A (ru) | 2013-12-10 |
| US20120252780A1 (en) | 2012-10-04 |
| EP2493888A1 (fr) | 2012-09-05 |
| EP2493888A4 (fr) | 2013-05-01 |
| EP2493888B1 (fr) | 2016-04-06 |
| WO2011059839A1 (fr) | 2011-05-19 |
| BR112012010010A2 (pt) | 2018-03-20 |
| CN102725291A (zh) | 2012-10-10 |
| CN102725291B (zh) | 2016-12-21 |
| KR20120092141A (ko) | 2012-08-20 |
| ES2574927T3 (es) | 2016-06-23 |
| IL219372A0 (en) | 2012-06-28 |
| CA2779303A1 (fr) | 2011-05-19 |
| RU2550821C2 (ru) | 2015-05-20 |
| MX2012004995A (es) | 2012-10-03 |
| AU2010319842A1 (en) | 2012-05-17 |
| JP2013509442A (ja) | 2013-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY149316A (en) | Sirtuin modulating imidazohiazole compounds | |
| MY160006A (en) | Thiazolopyridine sirtuin modulating compounds | |
| MX2009013977A (es) | Compuestos de tiazolopiridina moduladores de sirtuinas. | |
| EP2344475A4 (fr) | Quinazolinone, quinolone et analogues apparentés en tant que modulateurs de sirtuine | |
| MX2010012961A (es) | Imidazopiridina y analogos relacionados como moduladores de sirtuina. | |
| WO2009134973A8 (fr) | Quinoléines et analogues apparentés en tant que modulateurs de sirtuine | |
| MX2011006084A (es) | Isoindolinona y analogos relacionados como moduladores de sirtuina. | |
| MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
| MX2010005186A (es) | Tiazolopiridinas solubilizadas. | |
| MX2011009213A (es) | Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina. | |
| MX2010004965A (es) | Derivados de amida como moduladores de la sirtuina. | |
| WO2006094209A3 (fr) | Modulateurs de sirtuine a amide n-benzimidazolylalkyle substitue | |
| WO2006105440A3 (fr) | Nicotinamide riboside et analogues | |
| AU2014265671A8 (en) | Substituted bridged urea analogs as sirtuin modulators | |
| WO2007019344A8 (fr) | Dérivés d'imidazo [2,1-b] thiayole en tant que modulateurs de sirtuine | |
| EA201170137A1 (ru) | Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина | |
| BR112012010010A2 (pt) | piridinas bicíclicas e análogos como moduladores da sirtuína | |
| WO2006078941A3 (fr) | Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes | |
| WO2009085226A3 (fr) | Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation | |
| WO2007022225A3 (fr) | Composes nitres cycliques, compositions pharmaceutiques contenant ces composes et leurs applications | |
| CR9347A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| WO2006094210A3 (fr) | Modulateurs de sirtuine de tetrahydroquinoxalinone | |
| MX2017006658A (es) | Ánalogos de urea unidos sustituidos como moduladores de sirtuina. | |
| WO2006094246A3 (fr) | Modulateurs de sirtuine a base de n-arylmethyl benzamide | |
| MA32416B1 (fr) | 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation |